Source:http://linkedlifedata.com/resource/pubmed/id/12766879
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2003-5-26
|
pubmed:abstractText |
Tumor necrosis factor-alpha (TNF-alpha) antagonist therapy has proven effective in inflammatory conditions such as rheumatoid arthritis and Crohn's disease. There is substantial evidence that TNF-alpha also plays a role in the development of graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation, which along with leukemia relapse remains one of the 2 major impediments to success of the approach. Using a recently developed potent rat/mouse chimeric monoclonal antibody directed against murine TNF-alpha (CNTO2213), the authors investigated the effect of TNF-alpha blockade on GVHD mediated by either CD4(+) or CD8(+) donor T cells. The results indicated that the treatment had only a moderate effect on both a CD8(+) T cell-mediated major histocompatibility complex-matched GVHD model involving multiple minor histocompatibility antigens and a p-->F(1) acute GVHD model directed against a haplo-mismatched major histocompatibility complex barrier involving both CD4(+) and CD8(+) T cells. In contrast, treatment with the anti-TNF-alpha antibody had a highly significant effect (100% survival rate) on the CD4(+) T cell-mediated component of this latter model. Importantly, anti-TNF-alpha antibody did not block the development of a graft-versus-leukemia effect against a murine myeloid leukemia challenge in either a syngeneic or allogeneic p-->F(1) setting. This suggests that the inhibition of TNF-alpha during allogeneic hematopoietic cell transplantation may be able to diminish the inflammatory GVHD reaction without hindering effective graft-versus-leukemia responses.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
1083-8791
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
9
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
292-303
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:12766879-Animals,
pubmed-meshheading:12766879-Antibodies, Monoclonal,
pubmed-meshheading:12766879-Bone Marrow Transplantation,
pubmed-meshheading:12766879-CD4-Positive T-Lymphocytes,
pubmed-meshheading:12766879-CD8-Positive T-Lymphocytes,
pubmed-meshheading:12766879-Graft vs Host Disease,
pubmed-meshheading:12766879-Graft vs Leukemia Effect,
pubmed-meshheading:12766879-Male,
pubmed-meshheading:12766879-Mice,
pubmed-meshheading:12766879-Mice, Inbred Strains,
pubmed-meshheading:12766879-Recombinant Fusion Proteins,
pubmed-meshheading:12766879-Survival Rate,
pubmed-meshheading:12766879-Tumor Necrosis Factor-alpha
|
pubmed:year |
2003
|
pubmed:articleTitle |
Role of tumor necrosis factor-alpha in graft-versus-host disease and graft-versus-leukemia responses.
|
pubmed:affiliation |
Kimmel Cancer Institute, Jefferson Medical College, Philadelphia, Pennsylvania 19107, USA. R.Korngold@mail.jci.tju.edu
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|